PA
CPRX

Profund Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Profund Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Sell
57,544
-3,532
-6% -$84.1K 0.05% 258
2025
Q4 		$1.43M Buy
61,076
+23,304
+62% +$519K 0.04% 272
2025
Q3 		$744K Buy
37,772
+12,965
+52% +$267K 0.02% 397
2025
Q2 		$538K Sell
24,807
-1,204
-5% -$28.4K 0.02% 446
2025
Q1 		$631K Sell
26,011
-1,402
-5% -$31.6K 0.03% 410
2024
Q4 		$572K Sell
27,413
-1,705
-6% -$36.6K 0.02% 445
2024
Q3 		$579K Sell
29,118
-9,842
-25% -$182K 0.02% 471
2024
Q2 		$603K Sell
38,960
-41,182
-51% -$641K 0.02% 444
2024
Q1 		$1.28M Buy
80,142
+18,578
+30% +$280K 0.05% 294
2023
Q4 		$1.03M Sell
61,564
-27,895
-31% -$381K 0.04% 322
2023
Q3 		$1.05M Sell
89,459
-43,209
-33% -$578K 0.06% 272
2023
Q2 		$1.78M Buy
132,668
+42,534
+47% +$612K 0.1% 166
2023
Q1 		$1.49M Buy
90,134
+77,524
+615% +$1.28M 0.09% 184
2022
Q4 		$235K Buy
12,610
+55
+0.4% +$847 0.02% 803
2022
Q3 		$161K Buy
+12,555
New +$149K 0.01% 849

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Profund Advisors's CPRX Position: Q1 2026 in Review

Profund Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 5.8% in Q1 2026, selling an estimated $84.1K and leaving 57,544 shares worth $1.42M. The position accounts for 0.05% of the portfolio, ranked #258.

Profund Advisors first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.78M in Q2 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Profund Advisors held 57,544 shares of Catalyst Pharmaceutical worth $1.42M as of Q1 2026.
  • Profund Advisors sold 3,532 Catalyst Pharmaceutical shares in Q1 2026, an estimated $84.1K.
  • Catalyst Pharmaceutical made up 0.05% of Profund Advisors's portfolio in Q1 2026, its #258 holding.
  • Profund Advisors first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
  • Profund Advisors's Catalyst Pharmaceutical position peaked at $1.78M in Q2 2023.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.